Navigation Links
Transplant drug preserves kidneys, avoids toxicity
Date:3/3/2010

The experimental drug belatacept can prevent graft rejection in kidney transplant recipients while better preserving kidney function when compared with standard immunosuppressive drugs, data from two international phase III clinical trials show.

The results are published in the March issue of the American Journal of Transplantation.

The senior author of the paper describing BENEFIT (Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial) is Christian P. Larsen, MD, DPhil, director of the Emory Transplant Center and chair of the department of surgery at Emory University School of Medicine. The lead author is Flavio Vincenti, MD, professor of medicine (nephrology) at University of California, San Francisco.

Thomas C. Pearson, MD, DPhil, professor of surgery at Emory and co-director of the kidney/pancreas transplant program at Emory Transplant Center, is a co-author on a companion paper describing belatacept's performance on "extended criteria" kidney transplants (Kidneys from donors that are older or have other factors associated with shorter graft survival).

The drugs most transplant patients now rely on to inhibit their immune systems and prevent graft rejection have serious side effects. The class of drugs known as calcineurin inhibitors (cyclosporine and tacrolimus, for example) can damage the kidneys and lead to high blood pressure and diabetes.

The data from the BENEFIT trial, which tracked 666 kidney transplants at 100 sites around the world, shows that patients taking belatacept had similar graft survival rates to those taking cyclosporine, while maintaining higher kidney function and lower blood pressure and cholesterol. In addition, instead of requiring patients to take pills twice every day, in the case of calcineurin inhibitors, belatacept can be given every few weeks.

Trial data and side effects:

The BENEFIT trial, which was sponsored by Bristol Myers Squibb, compared three regimens: a more intensive and a less intensive course of belatacept treatment and a standard cyclosporine course.

All patients received a temporary course of an anti-T cell antibody called basiliximab and the standard transplant drugs mycophenolate mofetil and corticosteroids.

After one year, the proportion of patients with impaired kidney function (defined through glomerular filtration rate) was 55 percent for more intensive and 54 percent for less intensive, compared to 78 percent for cyclosporine. Patients' blood pressure, cholesterol and blood sugar profiles were also more favorable with belatacept.

More patients experienced acute rejection -- a temporary flare-up of the immune system against the donated kidney -- under belatacept (22 percent for more intensive, 17 percent for less) compared to 7 percent with cyclosporine. However, in most cases the acute rejection was successfully treated with drugs and did not lead to graft failure.

With belatacept, there was a higher incidence of a serious complication called post-transplant lymphoproliferative disorder (PTLD) five patients total in the BENEFIT trial, compared to one with cyclosporine. PTLD is associated with infection with the Epstein-Barr virus, which many humans have as a low-level chronic infection. The authors say PTLD might be reduced by avoiding use of belatacept in Epstein-Barr-nave patients.


'/>"/>

Contact: Holly Korschun
404-727-3990
Emory University
Source:Eurekalert

Related medicine news :

1. Preclinical study suggests organ-transplant drug may aid in lupus fight
2. Study provides hope that some transplant patients could live free of antirejection drugs
3. Study provides hope that some transplant patients could live free of anti-rejection drugs
4. Advanced Age No Bar to Liver Transplant
5. Circulating fats kill transplanted pancreas cells, study shows
6. Sexual function affected by stem cell transplant according to long-term study
7. Dallas-Area Transplant Meeting Puts Spotlight on Key Issues
8. American Society of Transplantations Past President Testifies Before Congress at Forum on Organ Donation
9. Scientists Spot Key to Kidney Transplant Success
10. Fetal cell transplant could be a hidden link between childbirth and reduced risk of breast cancer
11. Patients over age 60 do well after liver transplantation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... December 09, 2016 , ... Mediaplanet today announces distribution of ... while encouraging readers to sign up as an organ donor for the 123,000 people ... , An organ donor can save up to 8 saves through organ donation and ...
(Date:12/9/2016)... ... December 09, 2016 , ... "I had a terrible time trying to ... "I thought that if the nebulizer had a more child-friendly design, then children would ... He developed the patent-pending NEBY to avoid the need to deliver medication via a ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... with distinction by the Undersea and Hyperbaric Medical Society (UHMS), the leading authority ... care and patient safety. Only a few hospitals and facilities have earned this ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... “Natural Language Processing–Enabled and Conventional Data Capture Methods for Input to Electronic Health ... . , Results of the comparative usability study demonstrate that a dictation-based method ...
(Date:12/8/2016)... ... December 08, 2016 , ... CURE Media Group, the nation’s ... groups, has aligned with Upstage Lung Cancer in efforts to combat lung cancer, announced ... J. Hennessy, Jr said, “CURE Media Group is honored to team up with Upstage ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... Dec 9, 2016 Research and Markets has ... report to their offering. ... The global travel vaccines market to grow at ... report covers the present scenario and the growth prospects of the ... the report considers the revenue generated from the sales of various ...
(Date:12/8/2016)... -- Australia Ophthalmic Lasers Market Outlook to 2022 ... Outlook to 2022", provides key market data on the ... millions of US dollars, volume (in units) and average ... Lasers and YAG Lasers. The report also provides ... these market segements, and global corporate-level profiles of the ...
(Date:12/8/2016)... , Dec. 8, 2016 KEY FINDINGS ... poised to grow in 2017-2023. Various reasons for growth ... obese population, higher incidences of chronic diseases, high recovery ... mobility aid services. Medical lifting sling refers to ... with limited mobility. These slings connect to the lift ...
Breaking Medicine Technology: